Nexalin Technology (NXL) EBITDA Margin (2021 - 2026)
Nexalin Technology (NXL) recorded quarterly EBITDA Margin of 14025.08% in Q1 2026, down 914.87% quarter-over-quarter from 1381.95% in Q4 2025, and down 917927.0% on a YoY basis from N/an in Q1 2025.
Nexalin Technology (NXL) EBITDA Margin (2021 - 2026) Analysis & Trends
Nexalin Technology's EBITDA Margin history runs 6 years deep, the most recent figure standing at 14025.08% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 917927.0% year-over-year to 14025.08%; the TTM figure through Mar 2026 stood at 3022.88% (up 350350.0% YoY), while the FY2025 annual figure was 2725.46%, up 178334.0% from the prior year.
- EBITDA Margin was 14025.08% for Q1 2026 at Nexalin Technology, down from 1381.95% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 24.83% in Q3 2022 to a low of 14025.08% in Q1 2026.
- Historically, EBITDA Margin has averaged 4620.77% across 5 years, with a median of 2336.57% in 2023.
- The sharpest annual moves came in 2023 and 2025: EBITDA Margin slumped 963584 bps in 2023, then surged 904324 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 1804.51% in 2022, then plunged by 111 bps to 3807.33% in 2023, then plunged by 174 bps to 10425.19% in 2024, then jumped by 87 bps to 1381.95% in 2025, then plunged by 915 bps to 14025.08% in 2026.
- The last three EBITDA Margin figures came in at 14025.08% (Q1 2026), 1381.95% (Q4 2025), and 12550.4% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 14.52% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 19.94% |
| 10 | Nexalin Technology | 7.82 Mn | 5.11 Mn | 13,133.00 | -14,025.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,025.08% |
| Dec 31, 2025 | -1,381.95% |
| Sep 30, 2025 | -12,550.40% |
| Jun 30, 2025 | -2,239.01% |
| Mar 31, 2025 | -4,845.81% |
| Dec 31, 2024 | -10,425.19% |
| Sep 30, 2024 | -6,795.76% |
| Jun 30, 2024 | -4,784.83% |
| Mar 31, 2024 | -1,323.23% |
| Dec 31, 2023 | -3,807.33% |
| Sep 30, 2023 | -9,660.67% |
| Jun 30, 2023 | -2,336.57% |
| Mar 31, 2023 | -2,314.61% |
| Dec 31, 2022 | -1,804.51% |
| Sep 30, 2022 | -24.83% |
| Jun 30, 2022 | -111.61% |
| Mar 31, 2022 | -121.63% |
| Dec 31, 2021 | -2,406.30% |
| Sep 30, 2021 | -3,207.88% |